Pfizer suspends worldwide studies for tanezumab in osteoarthritis
This article was originally published in Scrip
Executive Summary
Pfizer has suspended worldwide clinical trials of its investigational pain drug, tanezumab, for osteoarthritis at the request of the US FDA after some patients receiving the drug experienced a worsening of their osteoarthritis that led to joint replacement. Trials for this population had reached the Phase III stage.
You may also be interested in...
Regeneron Partners NGF Antibody With Teva To Mitigate Risks
Regeneron and Teva will partner on the development and commercialization of the late-stage nerve growth factor antibody fasinumab for pain in a deal that will help Regeneron fund a 10,000-patient safety database.
Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains
Regeneron Pharmaceuticals Inc. reported statistically significant pain relief for osteoarthritis sufferers enrolled in the company's Phase II/III clinical trial for fasinumab, but the data didn't relieve concerns about neuro-musculoskeletal side effects for medicines that inhibit nerve growth factor (NGF).
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.